OQS
VKTX icon

Occudo Quantitative Strategies’s Viking Therapeutics VKTX Stock Holding History

Occudo Quantitative Strategies’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,001
Closed -$239K – 888
2025
Q2 		$239K Buy
+9,001
New +$237K 0.03% 512
2023
Q4 		– Sell
-16,388
Closed -$181K – 1227
2023
Q3 		$181K Buy
+16,388
New +$234K 0.02% 809
2021
Q1 		– Sell
-57,746
Closed -$325K – 939
2020
Q4 		$325K Buy
+57,746
New +$350K 0.1% 386

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Occudo Quantitative Strategies's VKTX Position: Q3 2025 in Review

Occudo Quantitative Strategies sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 9,001 shares — an estimated $239K sold.

Occudo Quantitative Strategies first reported a position in VKTX in Q4 2020 and held it in 3 quarters. The position peaked at $325K in Q4 2020. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Occudo Quantitative Strategies reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 9,001 Viking Therapeutics shares in Q3 2025, an estimated $239K.
  • Occudo Quantitative Strategies first reported a position in Viking Therapeutics in Q4 2020 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Viking Therapeutics position peaked at $325K in Q4 2020.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.